Condition: Wet Age-related Macular Degeneration (wAMD) · Sponsor: Beijing Anlong Biopharmaceutical Co., Ltd.
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.
This description comes directly from the study's public registry record.
AnlongBio · +86-010-80414166 · info@anlongbio.com
Always discuss trial participation with your own doctor first.
| Chinese Academy of Medical Sciences & Peking Union Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06718816